56218-62-3

Basic information

• Product Name: Acetyl chloride, [[(4-methylphenyl)sulfonyl]amino]-
• CAS NO: 56218-62-3
• Molecular Formula: C9H10ClNO3S
• Molecular Weight: 247.702
• Mol File: 56218-62-3.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Acetyl chloride, [[(4-methylphenyl)sulfonyl]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetyl chloride, [[(4-methylphenyl)sulfonyl]amino]-(56218-62-3)
• EPA Substance Registry System: Acetyl chloride, [[(4-methylphenyl)sulfonyl]amino]-(56218-62-3)

Safety Data

• Hazardous Substances Data: 56218-62-3(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 1080-44-0 N-Tosylglycine 
• 114004-56-7 1,1-Bis--dimethylaether> 

Downstream Products

• 101399-34-2 N-[N-(toluene-4-sulfonyl)-glycyl]-serine methyl ester 
• 4127-97-3 2-amino-3-{[N-(toluene-4-sulfonyl)-glycyl]-amino}-propionic acid 
• 103640-05-7 N-(toluene-4-sulfonyl)-glycine dimethylamide 
• 2478-44-6 2-[[(4-methylphenyl)sulfonyl]amino]-N-phenylacetamide 
• 2478-45-7 Tos-Gly-Gly-OEt 
• 95021-64-0 1,4-bis[(4-methylphenyl)sulfonyl]tetrahydropyrazine-2,5-dione 
• 80837-64-5 N-[2-(2-Chloro-benzoyl)-4-nitro-phenyl]-2-(toluene-4-sulfonylamino)-acetamide 
• 80613-63-4 2-Oxo-6-[2-(toluene-4-sulfonylamino)-acetylamino]-2H-chromene-3-carboxylic acid methyl ester 
• 86233-00-3 N-[2-((Z)-8-Bromo-2-oxo-6-phenyl-2,3-dihydro-1H-benzo[f][1,2,5]triazocin-4-yl)-2-oxo-ethyl]-4-methyl-benzenesulfonamide 
• 80837-60-1 2-(4-Toluolsulfonylglycylamino)-5-chlorbenzophenon 
• 109968-91-4 N_α-(Tosylglycyl-L-prolyl)-D,L-4-cyanphenylalanin 
• 92842-16-5 Nα-(Tosylglycyl)-4-cyan-phenylalanin 
• 84792-43-8 N_α-(Tosylglycyl)-3-cyanphenylalanin 
• 4703-34-8 N-(p-tosyl)glycylglycine 

Relevant articles and documents

New lactam-containing benzenesulfonamides: design, synthesis, and in silico and in vitro studies

A virtual set of new lactam-containing derivatives of arylsulfonylglycines 1a–d and 2a–d was designed and analyzed using structure–activity computer models (web-services PASS Online, AntiBac-Pred, and GUSAR Acutetoxicity). The antimicrobial activity again

Metal-Free N–H/C–H Coupling for Efficient Asymmetric Synthesis of Chiral Dihydroquinoxalinones from Readily Available α-Amino Acids

We have developed a method for the synthesis of dihydroquinoxalinones via intramolecular N–H/C–H coupling using hypervalent iodine. The starting materials were prepared from inexpensive and readily available aniline and amino acid derivatives. Various functional groups were tolerated to give multisubstituted dihydroquinoxalinones in moderate to excellent yields. The chirality of the amino acid was transferred to the desired target compound without a loss of enantiomeric excess. Preliminary mechanistic studies indicated that the reaction proceeds via an ionic mechanism.

SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growthinvitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.